Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Geoffrey, Kim"'
Autor:
Yujia Xia, Jie Zhou, Xiaolei Xun, Luke Johnston, Ting Wei, Ruitian Gao, Yufei Zhang, Bobby Reddy, Chao Liu, Geoffrey Kim, Jin Zhang, Shuai Zhao, Zhangsheng Yu
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-17 (2024)
Abstract Accurate treatment response assessment using serial CT scans is essential in oncological clinical trials. However, oncologists’ assessment following the Response Evaluation Criteria in Solid Tumors (RECIST) guideline is subjective, time-co
Externí odkaz:
https://doaj.org/article/297a12aa3d214160a57f0bc814fdc012
Autor:
Yujia Xia, Jie Zhou, Xiaolei Xun, Jin Zhang, Ting Wei, Ruitian Gao, Bobby Reddy, Chao Liu, Geoffrey Kim, Zhangsheng Yu
Publikováno v:
Insights into Imaging, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Objectives To develop a deep learning model combining CT scans and clinical information to predict overall survival in advanced hepatocellular carcinoma (HCC). Methods This retrospective study included immunotherapy-treated advanced HCC pati
Externí odkaz:
https://doaj.org/article/2f26432388084013b054686cf3364d9f
Autor:
Xiajing Gong, Meng Hu, Jinzhong Liu, Geoffrey Kim, James Xu, Amy McKee, Todd Palmby, R. Angelo de Claro, Liang Zhao
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
Small molecule kinase inhibitors (SMKIs) are being approved at a fast pace under expedited programs for anticancer treatment. Here, the authors employ a machine-learning model to examine the relationships between kinase targets and adverse events in
Externí odkaz:
https://doaj.org/article/0acfd12fa2c4416da16ad933f8db2dd9
Autor:
Boris Shulgin, Yuri Kosinsky, Andrey Omelchenko, Lulu Chu, Ganesh Mugundu, Sergey Aksenov, Rodrigo Pimentel, Garrett DeYulia, Geoffrey Kim, Kirill Peskov, Gabriel Helmlinger
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Programmed cell death-1 (PD-1) and/or cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) immune checkpoint inhibitor (ICI) treatments are associated with adverse events (AEs), which may be dependent on ICI dose. Applying a model-based meta-analys
Externí odkaz:
https://doaj.org/article/ba6cbaee68e24581a253dccc7dd7c5d1
Autor:
Reena Philip, Richard Pazdur, Geoffrey Kim, Amy E. McKee, Gideon M. Blumenthal, Abraham Tzou, Julia A. Beaver
Supplementary Table S1: Complex Signature Oncology In Vitro Diagnostic Devices
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08bf59ad31e66a30d44e3bd5e085b067
https://doi.org/10.1158/1078-0432.22462790
https://doi.org/10.1158/1078-0432.22462790
Autor:
Reena Philip, Richard Pazdur, Geoffrey Kim, Amy E. McKee, Gideon M. Blumenthal, Abraham Tzou, Julia A. Beaver
As technologies evolve, and diagnostics move from detection of single biomarkers toward complex signatures, an increase in the clinical use and regulatory submission of complex signatures is anticipated. However, to date, no complex signatures have b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba0f51102e805bb033991a39c86ad42e
https://doi.org/10.1158/1078-0432.c.6525209.v1
https://doi.org/10.1158/1078-0432.c.6525209.v1
Autor:
Bob T. Li, Bobby Daly, Mary Gospodarowicz, Monica M. Bertagnolli, Otis W. Brawley, Bruce A. Chabner, Lola Fashoyin-Aje, R. Angelo de Claro, Elizabeth Franklin, Jennifer Mills, Jeff Legos, Karen Kaucic, Mark Li, Lydia The, Tina Hou, Ting-Hui Wu, Bjorn Albrecht, Yi Shao, Justin Finnegan, Jing Qian, Javad Shahidi, Eduard Gasal, Craig Tendler, Geoffrey Kim, James Yan, Phuong Khanh Morrow, Charles S. Fuchs, Lianshan Zhang, Robert LaCaze, Stefan Oelrich, Martin J. Murphy, Richard Pazdur, Kevin Rudd, Yi-Long Wu
Publikováno v:
Nature Medicine. 28:620-626
Autor:
Calvin Chen Sheng, MD, Laleh Amiri-Kordestani, MD, Todd Palmby, PhD, Thomas Force, MD, Charles C. Hong, MD, PhD, Joseph C. Wu, MD, PhD, Kevin Croce, MD, PhD, Geoffrey Kim, MD, Javid Moslehi, MD
Publikováno v:
JACC: Basic to Translational Science, Vol 1, Iss 5, Pp 386-398 (2016)
Cardiotoxicity is a well-established complication of oncology therapies. Cardiomyopathy resulting from anthracyclines is a classic example. In the past decade, an explosion of novel cancer therapies, often targeted and more specific than conventional
Externí odkaz:
https://doaj.org/article/6158e6de3f1f4ac5ad684e83913463ba
Autor:
Amna Ibrahim, Erik Bloomquist, Shenghui Tang, Amy E. McKee, Suparna Wedam, Rajeshwari Sridhara, Geoffrey Kim, Kirsten B. Goldberg, Julia A. Beaver, Richard Pazdur, Laleh Amiri-Kordestani, Paul G. Kluetz
Publikováno v:
Journal of Clinical Oncology. 36:1225-1231
Purpose The outcome and proportion of patients with bone-only (BO) metastatic breast cancer (MBC) has not been well described. We sought to describe the differential outcomes of patients with BO MBC in clinical trials and explore whether there was a
Publikováno v:
Clinical and Translational Science. 11:345-351
Today’s cancer therapy has made substantial progresses. Recent success in immuno-oncology (IO) has generated enormous excitement and expectation. With the existing and novel therapies, combination therapies provide opportunities to coordinate actio